Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTI-104
- Development stage
- Preclinical
- Lead developer
- Postsurgical Therapeutics
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Oral
01
Overview
**PTI-104** is a preclinical Postsurgical Therapeutics oncology program using the CLOTT approach for combinatorial local and oral targeted therapy in KRAS-mutated solid tumors. The program combines everolimus, an mTOR-pathway inhibitor, with trametinib, a MEK-pathway inhibitor, and uses PLGA-based controlled-release local delivery technology intended to provide sustained intratumoral exposure while limiting systemic toxicity. Postsurgical reports that non-GLP efficacy animal testing is in progress. ([pstherapeutics.com](https://pstherapeutics.com/pipeline-projects.html))
- Other names
- CLOTTCLOTT PlatformPTI104PTI-104PTI 104
02
Targets
mTOR (Mammalian target of rapamycin kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on PTI-104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTI-104.